secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036410
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports FY 2023 net loss of $60.4M; IPO raised $366.9M in Feb 2024
--------------------------------------------------------------------------

- Net loss $60.4M ($89.61/share) vs. $28.9M ($63.43/share) in FY 2022; cash burn $52.4M in operating activities.
- Cash, equivalents and marketable securities $57.5M as of Dec 31, 2023; Feb 2024 IPO gross proceeds ~$366.9M.
- Treated 14 autoimmune patients with KYV-101 CAR T therapy; FDA cleared Phase 2 trials in MS, MG and Phase 1/2 in systemic sclerosis.
- Received FDA Fast Track Designations for KYV-101 in refractory MG, refractory progressive MS, and lupus nephritis.
- Upcoming data releases at EULAR (Q2 2024), ECTRIMS (Q3 2024) and ACR (Q4 2024) for KYV-101.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/0000950170-24-036410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/8k_for_earnings_release_.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer